Results 

Alliance delivers the right medicine

Alliance delivers the right medicine

Adjusted pre-tax profits of £28.1m at Alliance Pharma (APH) were bang in line with broker Investec’s forecast, as well as numbers already disclosed in a January pre-close trading update. That left little room for surprises on results day, particularly as the ‘international star’ product portfolio continues to perform well. Products in this portfolio have “a distinct USP”, says chief executive Peter Butterfield, as well as high margins, a range of international rights and future growth potential.  

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now